Novartis: Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients

Novartis announced today that the full data from the LIBERTY study of Aimovig (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet.

Source link

Related posts

Researchers Contribute to Important Neurological Discovery


neurosciencenews: Upbeat music can sweeten tough…


No Edge for Levetiracetam Over Phenytoin for Status Epilepticus


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy